

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Christopher J. M. MEADE et al.

Examiner: P. Spivack

Serial No.: 10/614,362

Group Art Unit: 1614

Filed: July 7, 2003

Confirmation No.: 7889

Title: NEW PHARMACEUTICAL COMPOSITIONS BASED ON NEW
ANTICHOLINERGICS AND NK₁ RECEPTOR ANTAGONISTS

RESPONSE TO REQUIREMENT FOR ELECTION OF SPECIES

Mail Stop
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In response to the Office Action mailed August 18, 2008, and the requirement for an election of species therein, applicants hereby elect the species wherein the formulation is a propellant-free inhalable solution or suspension. It is believed that claims 1-10, 20-31, 35 and 37 encompass embodiments directed to the elected species.

The Examiner is encouraged to examine the broadest possible scope of invention indicated by the elected species.

In accordance with M.P.E.P. §803.02 and as stated in the Office action, should no prior art be found which renders the invention of the elected species unpatentable, the search of the remainder of the generic claim(s) should be continued in the same application. The withdrawal of the previous restriction requirement is acknowledged.

Favorable action is earnestly solicited.

The Commissioner is hereby authorized to charge any additional fees necessary to filing this response or credit any overpayment to Deposit Account No. 13-3402.

Respectfully submitted,

/John A. Sopp/

John A. Sopp, Reg. No. 33,103
Attorney for Applicants

MILLEN, WHITE, ZELANO & BRANIGAN, P.C.
Arlington Courthouse Plaza 1, Suite 1400
2200 Clarendon Boulevard
Arlington, Virginia 22201
Telephone: (703) 243-6333
Facsimile: (703) 243-6410

Date: September 18, 2008

Attorney Docket No. 01-1363

JAS/sb